sb-705498
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00281684)
Timeline
Indications
Mechanism of action
- Vanilloid receptorANTAGONIST
TRPV1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1- Mol. weight
- 429.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL207433 ↗
Also known as
- gsk705498
- gsk705498
- n-(2-bromophenyl)-n'-((1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl))urea
- sb705498
- sb705498
- sb705498
- sb 705498
- sb-705498
- sb-705498
- sb-705498
- sb-705498
- sb-705498
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01673529 | Phase 1 | Jul 17, 2012 | GlaxoSmithKline |
| NCT01424397 | Phase 2 | Apr 1, 2011 | GlaxoSmithKline |
| NCT01476098 | Phase 2 | Apr 1, 2011 | GlaxoSmithKline |
| NCT01424514 | Phase 2 | Dec 1, 2010 | GlaxoSmithKline |
| NCT01439308 | Phase 2 | Dec 1, 2009 | GlaxoSmithKline |
| NCT00907933 | Phase 1 | Nov 1, 2008 | GlaxoSmithKline |
| NCT00731250 | Phase 1 | Jul 1, 2008 | GlaxoSmithKline |
| NCT00461682 | Phase 2 | Jan 26, 2007 | GlaxoSmithKline |
| NCT00269022 | Phase 2 | Jan 1, 2006 | GlaxoSmithKline |
| NCT00281684 | Phase 2 | Dec 1, 2005 | GlaxoSmithKline |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 2 | 2005 |
1 organizations
Page 1 / 1